BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34168072)

  • 1. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
    Moore DA; Balbi KJ; Poskitt B; Bennett P
    J Clin Pathol; 2022 Mar; 75(3):209-210. PubMed ID: 34168072
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
    de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
    PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.
    Penzel R; Sers C; Chen Y; Lehmann-Mühlenhoff U; Merkelbach-Bruse S; Jung A; Kirchner T; Büttner R; Kreipe HH; Petersen I; Dietel M; Schirmacher P
    Virchows Arch; 2011 Jan; 458(1):95-8. PubMed ID: 21057810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
    Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive detection of EGFR deletion at exon 19 in non-small cell lung cancer by real time diagnostic.
    Sun H; Gan ZC; Gao JJ; Zheng F
    Clin Lab; 2014; 60(9):1517-26. PubMed ID: 25291948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
    Riely GL
    J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
    Fang S; Wang Z
    Drug Des Devel Ther; 2014; 8():1595-611. PubMed ID: 25302015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Sukari A; Nagasaka M; Wakeling E
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1188-1192. PubMed ID: 28982744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
    Marchetti A; Del Grammastro M; Felicioni L; Malatesta S; Filice G; Centi I; De Pas T; Santoro A; Chella A; Brandes AA; Venturino P; Cuccurullo F; Crinò L; Buttitta F
    PLoS One; 2014; 9(8):e103883. PubMed ID: 25137181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved EGFR mutation detection sensitivity after enrichment by Cas9/sgRNA digestion and PCR amplification.
    Wang L; Jiang J; Li X; Li K; He R; Li J; Duan L; Luo W; Hu Z; Luo D
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1316-1324. PubMed ID: 33216845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
    J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
    Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
    PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.